Transparency in our dealings with the Healthcare and Patient Communities
GW is passionate about advancing medicines in the fields of cannabinoid science and developing therapies to address serious medical needs with limited treatment options, particularly in neurological conditions. Healthcare professionals, healthcare organisations and the patient community all have an important role to play in this work. There is much that we can learn from them about the conditions they treat or live with as well as the everyday practical use of our medicines. This collaboration is essential to drive innovation in the development of medicines and to deliver the best treatment options for patients.
We also recognise that it is crucial that patients and the public have faith in our industry and the important work we are carrying out to advance research and treatment in areas of high unmet need. That is why we are committed to transparency in our financial dealings with the healthcare and patient communities.
To the extent we are permitted by law, we disclose our payments to healthcare professionals and healthcare organisations in the United Kingdom on the ABPI Disclosure platform annually on or around 30th of June covering the previous calendar year. Payments in France are published on the DGS (Department of the Ministry of Health) National Public Platform by 1st September of each year for the benefits granted during the first half of the year and by 1st March of each year for the benefits granted during the second half of the preceding year. All other payments to HCPs in other countries outside of the United States are uploaded to our websites.
Patient Organisation Support
GW was founded to respond to the needs of patients. As a result, we understand the importance of partnering with Patient Organisations, patients and carers in order to deliver better medicines and better outcomes for patients. GW has a legitimate interest in supporting initiatives and organisations related to the advancement of research, disease awareness, education, and patient programs. GW also relies upon the expert knowledge provided by patient organisations. As such, the principle purpose of exchange with Patient Organisations is to enhance patient care, improve the lives of patients and improve the health of communities which we serve. Increasing transparent engagements with Patient Organisations has led to better trials, better engagements and greater communication throughout the life cycle of medicines. This has resulted in better patient outcomes.
GW is committed to disclosing transparently all financial support and significant non-financial support given to Patient Organisations.